Page 82 - Read Online

Cordero et al. Bioresorbable scaffolds in acute coronary syndrome

M, Wijns W, Witkowski A, Kolh P, Jüni P. Revascularisation versus Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth
medical treatment in patients with stable coronary artery disease: DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS;
network meta-analysis. BMJ 2014;348:g3859. COURAGE Trial Research Group. Optimal medical therapy with or
9. Onuma Y, Serruys PW, Perkins LE, Okamura T, Gonzalo N, Garcia- without PCI for stable coronary disease. N Engl J Med 2007;356:1503-
Garcia HM, Regar E, Kamberi M, Powers JC, Rapoza R, van 16.
Beusekom H, van der Giessen W, Virmani R. Intracoronary optical 21. Iqbal J, Zhang YJ, Holmes DR, Morice MC, Mack MJ, Kappetein
coherence tomography and histology at 1 month and 2, 3, and 4 AP, Feldman T, Stahle E, Escaned J, Banning AP, Gunn JP, Colombo
years after implantation of everolimus-eluting bioresorbable vascular A, Steyerberg EW, Mohr FW, Serruys PW. Optimal medical therapy
scaffolds in a porcine coronary artery model: an attempt to decipher improves clinical outcomes in patients undergoing revascularization
the human optical coherence tomography images in the ABSORB with percutaneous coronary intervention or coronary artery bypass
trial. Circulation 2010;122:2288-300. grafting: insights from the synergy between percutaneous coronary
10. Tamai H, Igaki K, Kyo E, Kosuga K, Kawashima A, Matsui S, intervention with TAXUS and cardiac surgery (SYNTAX) trial at the
Komori H, Tsuji T, Motohara S, Uehata H. Initial and 6-month 5-year follow-up. Circulation 2015;131:1269-77.
results of biodegradable poly-l-lactic acid coronary stents in humans. 22. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum
Circulation 2000;102:399-404. CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM,
11. Serruys PW, Chevalier B, Sotomi Y, Cequier A, Carrie D, Piek JJ, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson
Van Boven AJ, Dominici M, Dudek D, McClean D, Helqvist S, PW; American College of Cardiology/American Heart Association
Haude M, Reith S, de Sousa Almeida M, Campo G, Iniguez A, Sabate Task Force on Practice Guidelines. 2013 ACC/AHA Guideline on the
M, Windecker S, Onuma Y. Comparison of an everolimus-eluting treatment of blood cholesterol to reduce atherosclerotic cardiovascular
bioresorbable scaffold with an everolimus-eluting metallic stent for risk in adults: a report of the American College of Cardiology/
the treatment of coronary artery stenosis (ABSORB II): a 3 year, American Heart Association Task Force on Practice Guidelines. J Am
randomised, controlled, single-blind, multicentre clinical trial. Lancet Coll Cardiol 2014;63:2889-934.
2016;388:2479-91. 23. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ,
12. Cassese S, Byrne RA, Ndrepepa G, Kufner S, Wiebe J, Repp J, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR,
Schunkert H, Fusaro M, Kimura T, Kastrati A. Everolimus-eluting Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren
bioresorbable vascular scaffolds versus everolimus-eluting metallic WM, Vlachopoulos C, Wood DA, Zamorano JL. 2016 ESC/EAS
stents: a meta-analysis of randomised controlled trials. Lancet Guidelines for the management of dyslipidaemias: the Task Force
2016;387:537-44. for the Management of Dyslipidaemias of the European Society of
13. Lu C, Filion KB, Eisenberg MJ. The safety and efficacy of Absorb Cardiology (ESC) and European Atherosclerosis Society (EAS)
bioresorbable vascular scaffold: a systematic review. Clin Cardiol developed with the special contribution of the European Assocciation
2016;39:48-55. for Cardiovascular Prevention & Rehabilitation (EACPR).
14. Gori T, Schulz E, Hink U, Wenzel P, Post F, Jabs A, Münzel T. Early Atherosclerosis 2016;253:281-344.
outcome after implantation of Absorb bioresorbable drug-eluting 24. Rogers JK, Pocock SJ, McMurray JJ, Granger CB, Michelson EL,
scaffolds in patients with acute coronary syndromes. EuroIntervention Ostergren J, Pfeffer MA, Solomon SD, Swedberg K, Yusuf S.
2014;9:1036-41. Analysing recurrent hospitalizations in heart failure: a review of
15. Kočka V, Malý M, Toušek P, Buděšínský T, Lisa L, Prodanov statistical methodology, with application to CHARM-Preserved. Eur
P, Jarkovský J, Widimský P. Bioresorbable vascular scaffolds in J Heart Fail 2014;16:33-40.
acute ST-segment elevation myocardial infarction: a prospective 25. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V,
multicentre study ‘Prague 19’. Eur Heart J 2014;35:787-94. Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati
16. Cordero A, Moreno-Arribas J, Bertomeu-González V, Agudo P, A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ,
Miralles B, Masiá MD, López-Palop R, Bertomeu-Martinez V. Low Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L,
levels of high-density lipoproteins cholesterol are independently Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS Guidelines
associated with acute coronary heart disease in patients hospitalized on myocardial revascularization: the Task Force on Myocardial
for chest pain. Rev Esp Cardiol 2012;65:319-25. Revascularization of the European Society of Cardiology (ESC) and
17. Farooq V, Serruys PW, Garcia-Garcia HM, Zhang Y, Bourantas CV, the European Association for Cardio-Thoracic Surgery (EACTS)
Holmes DR, Mack M, Feldman T, Morice MC, Stahle E, James S, developed with the special contribution of the European Association
Colombo A, Diletti R, Papafaklis MI, de Vries T, Morel MA, van Es of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J
GA, Mohr FW, Dawkins KD, Kappetein AP, Sianos G, Boersma E. 2014;35:2541-619.
The negative impact of incomplete angiographic revascularization 26. Karanasos A, Simsek C, Gnanadesigan M, van Ditzhuijzen NS, Freire
on clinical outcomes and its association with total occlusions: the R, Dijkstra J, Tu S, Van Mieghem N, van Soest G, de Jaegere P,
SYNTAX (Synergy Between Percutaneous Coronary Intervention with Serruys PW, Zijlstra F, van Geuns RJ, Regar E. OCT assessment of the
Taxus and Cardiac Surgery) trial. J Am Coll Cardiol 2013;61:282-94. long-term vascular healing response 5 years after everolimus-eluting
18. Garcia S, Sandoval Y, Roukoz H, Adabag S, Canoniero M, bioresorbable vascular scaffold. J Am Coll Cardiol 2014;64:2343-56.
Yannopoulos D, Brilakis ES. Outcomes after complete versus 27. Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz
incomplete revascularization of patients with multivessel coronary GS, Mehran R, McPherson J, Farhat N, Marso SP, Parise H, Templin
artery disease: a meta-analysis of 89,883 patients enrolled in B, White R, Zhang Z, Serruys PW; PROSPECT Investigators. A
randomized clinical trials and observational studies. J Am Coll prospective natural-history study of coronary atherosclerosis. N Engl
Cardiol 2013;62:1421-31. J Med 2011;364:226-35.
19. Sachdev M, Sun JL, Tsiatis AA, Nelson CL, Mark DB, Jollis JG. The 28. Taniwaki M, Stefanini GG, Silber S, Richardt G, Vranckx P,
prognostic importance of comorbidity for mortality in patients with Serruys PW, Buszman PE, Kelbaek H, Windecker S; RESOLUTE
stable coronary artery disease. J Am Coll Cardiol 2004;43:576-82. All-Comers Investigators. 4-year clinical outcomes and predictors
20. Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk of repeat revascularization in patients treated with new-generation
WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, drug-eluting stents: a report from the RESOLUTE All-Comers trial
Vessel Plus ¦ Volume 1 ¦ June 27, 2017 75